8-K: Recursion Registers 7M Shares for Tempus Resale

Recursion Pharmaceuticals filed a prospectus supplement to register 7,088,742 Class A common shares for resale by Tempus AI, Inc., issued as payment for annual license fees.

Summary

• Recursion Pharmaceuticals, Inc. (RXRX) filed a prospectus supplement on November 26, 2025, along with an accompanying base prospectus.
• The purpose of this filing is to register for resale 7,088,742 shares of Recursion's Class A common stock, referred to as the 'Tempus Shares'.
• These Tempus Shares were issued to Tempus AI, Inc. (f/k/a Tempus Labs, Inc.) on November 24, 2025.
• The shares were issued as payment for annual license fees under the terms of a Master Agreement between Recursion and Tempus, as previously described in a Form 8-K filed on November 9, 2023.
• The registration is part of Recursion's automatic shelf Registration Statement on Form S-3ASR (File No. 333-284878), which was initially filed on February 12, 2025.
• The original offering of these shares to Tempus AI, Inc. was made pursuant to an exemption from registration under the Securities Act of 1933.
• Wilson Sonsini Goodrich & Rosati, P.C. provided a legal opinion confirming the legality of the Tempus Shares.

Sentiment

Score: 5

Explanation: The filing is largely procedural, registering shares for resale that were previously issued. While it enables potential future selling pressure, it also confirms the continuation of a strategic partnership, leading to a neutral overall sentiment.

Positives

• The issuance of shares to Tempus AI, Inc. as payment for annual license fees indicates the continuation and fulfillment of obligations under a strategic Master Agreement.
• The registration process ensures regulatory compliance, enabling Tempus AI, Inc. to legally resell the shares, which is a standard procedure for such equity payments.

Negatives

• The registration of 7,088,742 Class A common shares for resale by Tempus AI, Inc. could lead to an increase in the publicly traded float, potentially exerting downward pressure on the stock price if Tempus decides to sell a significant portion of these shares.

Risks

• Potential dilution of existing shareholder value if Tempus AI, Inc. sells a large number of the registered shares on the open market, increasing the supply of Class A common stock.

Future Outlook

The filing is procedural, enabling Tempus AI, Inc. to resell shares previously issued as payment. It does not provide forward-looking statements regarding Recursion's operational or financial performance, but facilitates the liquidity of shares related to an ongoing strategic partnership.

Industry Context

This type of share registration is a common procedural step in the biotechnology and pharmaceutical industries when shares are issued as consideration for partnerships, licensing agreements, or other strategic collaborations. It allows the recipient (Tempus AI, Inc.) to liquidate their equity payment in compliance with securities regulations, reflecting the ongoing financial mechanics of strategic alliances in the sector.

Comparison to Industry Standards

• This is a standard procedural filing for registering shares issued in a private transaction for public resale. It does not contain performance metrics or project results that would allow for direct comparison to specific comparable companies or industry benchmarks.

Related Party Transactions

• The issuance of 7,088,742 Class A common shares to Tempus AI, Inc. on November 24, 2025, was for annual license fees under a Master Agreement. This transaction represents a significant payment to a strategic partner.

Stakeholder Impact

• Existing shareholders may experience potential dilution if Tempus AI, Inc. sells a substantial portion of the 7,088,742 registered shares, increasing the supply of Class A common stock in the market.

Next Steps

• Tempus AI, Inc. is now able to offer and sell the 7,088,742 Class A common shares on the open market, subject to market conditions and their discretion.

Key Dates

Recommendation

This filing is a procedural update regarding the registration of shares for resale by a strategic partner, Tempus AI, Inc., which received these shares as payment for license fees. While the potential for 7,088,742 shares to enter the market could create some selling pressure and minor dilution, it does not reflect a change in Recursion's fundamental business operations or financial health. The event is expected following such share issuances. Therefore, a 'hold' recommendation is appropriate as it does not present a strong catalyst for either buying or selling based solely on this information.

Keywords

Recursion Pharmaceuticals, RXRX, Tempus AI, stock registration, S-3ASR, Class A common stock, share resale, license fees, biotechnology, pharmaceuticals